• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Warts - Pipeline Review, H2 2012 Product Image

Warts - Pipeline Review, H2 2012

  • ID: 2335315
  • November 2012
  • 64 pages
  • Global Markets Direct

Warts – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Warts - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Warts, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Warts. Warts - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Warts.
- A review of the Warts products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- READ MORE >

2
List of Tables 4
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Warts Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Warts 8
Warts Therapeutics under Development by Companies 10
Warts Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Discovery and Pre-Clinical Stage Products 16
Comparative Analysis 16
Warts Therapeutics – Products under Development by Companies 17
Warts Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Warts Therapeutics Development 19
Helix BioPharma Corp. 19
Inovio Biomedical Corporation 20
MediGene AG 21
Anaconda Pharma 22
BioMAS Ltd. 23
Telormedix SA 24
Cutanea Life Sciences 25
Genetic Immunity, LLC 26
Moberg Derma AB 27
FunZyme BioTechnologies S.A. 28
Warts – Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
interferon alpha-2b - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Veregen - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
TMX-202 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
AS-101 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Candin - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
cidofovir - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
plerixafor - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CLS003 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Albuterpenoid - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
HupaDerm Vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
imiquimod - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
AP-611074 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
SynCon HPV Vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Warts Therapeutics – Drug Profile Updates 50
Warts Therapeutics - Dormant Products 55
Warts – Product Development Milestones 56
Featured News & Press Releases 56
Jan 26, 2012: Hemispherx Biopharma Gains Regulatory Approval In Latin America For Alferon N Injection 56
Jan 25, 2012: Kaiser Permanente Study Finds Gardasil Does Not Trigger Lupus, Rheumatoid Arthritis Or Type 1 Diabetes After Vaccination 56
Jan 19, 2012: National Advisory Committee On Immunization Recommends Merck's GARDASIL 57
Dec 22, 2011: Helix BioPharma Files Clinical Trial Applications For Phase III Efficacy Trial Of Topical Interferon Alpha-2b In Patients With Low-Grade Cervical Lesions 58
Nov 15, 2011: Moberg Derma Receives SEK4m From Vinnova For Development Of Limtop 59
Aug 17, 2011: Hemispherx Biopharma Submits Regulatory Approval For Alferon In Argentina 59
Jul 01, 2011: Merck Receives Approval To Market GARDASIL In Japan 60
Apr 26, 2011: Merck Receives Health Canada Approval For Gardasil For Women Up To Age 45 60
Mar 25, 2011: FDA Approves Graceway’s Zyclara Cream For Treatment Of External Genital Warts 61
Jun 08, 2010: Helix BioPharma Corp Announces Phase II Clinical Trial Results of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 61
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 64
Disclaimer 64

List of Tables
Number of Products Under Development for Warts, H2 2012 8
Products under Development for Warts – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Helix BioPharma Corp., H2 2012 19
Inovio Biomedical Corporation, H2 2012 20
MediGene AG, H2 2012 21
Anaconda Pharma, H2 2012 22
BioMAS Ltd., H2 2012 23
Telormedix SA, H2 2012 24
Cutanea Life Sciences, H2 2012 25
Genetic Immunity, LLC, H2 2012 26
Moberg Derma AB, H2 2012 27
FunZyme BioTechnologies S.A., H2 2012 28
Assessment by Monotherapy Products, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 33
Warts Therapeutics – Drug Profile Updates 50
Warts Therapeutics – Dormant Products 55

List of Figures
Number of Products under Development for Warts, H2 2012 8
Products under Development for Warts – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Discovery and Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 29
Assessment by Route of Administration, H2 2012 30
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Molecule Type, H2 2012 32
Assessment by Stage and Molecule Type, H2 2012 33

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos